<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00966836</url>
  </required_header>
  <id_info>
    <org_study_id>PROTECT 2008-006980-35</org_study_id>
    <nct_id>NCT00966836</nct_id>
  </id_info>
  <brief_title>Prevention of Transplant Atherosclerosis With Everolimus and Anti-cytomegalovirus Therapy</brief_title>
  <acronym>PROTECT</acronym>
  <official_title>Efficacy and Safety of Anti-cytomegalovirus Prophylaxis Versus Pre-emptive Approaches With Valganciclovir in Heart Transplant Recipients Treated With Everolimus or Mycophenolate. A Randomized Open-label Study for Prevention of Cardiaca Allograft Vasculopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Bologna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Bologna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiac allograft vasculopathy (CAV) is the major cause of long-term graft failure in heart
      transplant recipients. Although several immune-mediated and metabolic risk factors have been
      implicated in the pathogenesis of CAV, no effective therapy is currently available to treat
      established CAV and prevent its adverse outcomes. Therefore, the main clinical strategy is
      based on prevention and treatment of factors known to trigger its development. Although the
      mechanism is vague, cytomegalovirus (CMV) infection is believed to play a key role in CAV
      progression.

      Two strategies involving administration of specific anti-CMV agents are recommended for
      prevention of CMV infection/disease: universal prophylaxis and preemptive therapy. The pros
      and cons of the two strategies are still debated, in the absence of randomized studies
      addressing graft-related outcomes and viral mechanisms of graft damage, and without any clear
      evidence of superiority of either approach.

      The investigators conceived this randomized prospective project to compare the effect of
      preemptive anti-CMV strategy with universal anti-CMV prophylaxis on CMV infection and on
      one-year increase in coronary intimal thickening. Patients will be additionally randomized to
      receive either mycophenolate mofetil or everolimus, in light of the possible anti-CMV
      properties of everolimus.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2009</start_date>
  <primary_completion_date type="Anticipated">April 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in maximal intimal thickness</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CMV infection</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Heart Transplantation</condition>
  <condition>Cardiac Allograft Vasculopathy</condition>
  <condition>Cytomegalovirus Infection</condition>
  <arm_group>
    <arm_group_label>Pre-emptive everolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Prophylaxis mycophenolate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Prophylaxis Everolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pre-emptive mycophenolate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pre-emptive strategy with valganciclovir plus everolimus</intervention_name>
    <description>Patients will be monitored for CMV infection and receive valganciclovir only for positive PCR or antigenemia. Everolimus plus cyclosporine and prednisone will be used for maintenance immunosuppression</description>
    <arm_group_label>Pre-emptive everolimus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prophylaxis with valganciclovir plus mycophenolate</intervention_name>
    <description>Patients will receive 3 months of oral valganciclovir with mycophenolate and standard cyclosporine and prednisone for maintenance immunosuppression</description>
    <arm_group_label>Prophylaxis mycophenolate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prophylaxis with valganciclovir plus everolimus</intervention_name>
    <description>Patients will receive valganciclovir for 3 months after transplant. Everolimus plus reduced cyclosporine and prednisone will be used for maintenance immunosuppression</description>
    <arm_group_label>Prophylaxis Everolimus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pre-emptive mycophenolate</intervention_name>
    <description>Patients will be monitored for CMV infection and receive valganciclovir only for positive PCR or antigenemia. Mycophenolate plus standard cyclosporine and prednisone will be used for maintenance immunosuppression</description>
    <arm_group_label>Pre-emptive mycophenolate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18y

          -  Heart or heart-kidney combined transplant

          -  Positive CMV serology at the time of transplant

          -  Glomerular filtration rate ≥ 20 ml/min/1.73m2 with MDRD at randomization.

          -  Written informed consent

        Exclusion Criteria:

          -  Panel Reactive Antibody ≥50%

          -  Less than 1000/mmc neutrophils at the time of randomization

          -  Less than 30,000/mmc platelets at the time of randomization

          -  Clinical significant infection in the 2 weeks prior to transplant

          -  Glomerular filtration rate &lt; 20 ml/min/1.73m2 estimated with MDRD formula at the time
             of randomization or hemodialysis treatment

          -  Intolerance towards valganciclovir, everolimus, mycophenolate or cyc-losporine

          -  Known contraindication to statin use

          -  Negative CMV serology at the time of transplant

          -  HIV positive testing

          -  Severe comorbidities that, based on investigator's judgment, contraindicate study
             drugs or procedures

          -  Potentially childbearing women who refuse to use contraceptives

          -  Participation to an interventional study in the 2 preceding weeks

          -  Unwillingness or inability to follow study procedure and to sign written in-formed
             consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Luciano Potena, MD PhD</last_name>
    <phone>+390516364526</phone>
    <email>luciano.potena2@unibo.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Francesco Grigioni, MD PhD</last_name>
    <phone>+390516364526</phone>
    <email>francesco.grigioni@unibo.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria S Orsola Malpighi</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Luciano Potena, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Potena L, Grigioni F, Magnani G, Lazzarotto T, Musuraca AC, Ortolani P, Coccolo F, Fallani F, Russo A, Branzi A. Prophylaxis versus preemptive anti-cytomegalovirus approach for prevention of allograft vasculopathy in heart transplant recipients. J Heart Lung Transplant. 2009 May;28(5):461-7. doi: 10.1016/j.healun.2009.02.009.</citation>
    <PMID>19416774</PMID>
  </reference>
  <reference>
    <citation>Potena L, Valantine HA. Cytomegalovirus-associated allograft rejection in heart transplant patients. Curr Opin Infect Dis. 2007 Aug;20(4):425-31. Review.</citation>
    <PMID>17609604</PMID>
  </reference>
  <reference>
    <citation>Hill JA, Hummel M, Starling RC, Kobashigawa JA, Perrone SV, Arizón JM, Simonsen S, Abeywickrama KH, Bara C. A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus. Transplantation. 2007 Dec 15;84(11):1436-42.</citation>
    <PMID>18091519</PMID>
  </reference>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2009</study_first_submitted>
  <study_first_submitted_qc>August 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2009</study_first_posted>
  <last_update_submitted>August 26, 2009</last_update_submitted>
  <last_update_submitted_qc>August 26, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2009</last_update_posted>
  <responsible_party>
    <name_title>Angelo Branzi</name_title>
    <organization>University of Bologna</organization>
  </responsible_party>
  <keyword>Heart Transplantation</keyword>
  <keyword>Cardiac Allograft Vasculopathy</keyword>
  <keyword>Cytomegalovirus Infection</keyword>
  <keyword>Everolimus</keyword>
  <keyword>Valganciclovir</keyword>
  <keyword>Mycophenolate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytomegalovirus Infections</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Valganciclovir</mesh_term>
    <mesh_term>Ganciclovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

